New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
11:14 EDTMYL, ISRG, ATHNOptions with increasing implied volatility: ATHN ISRG MYL
News For ATHN;ISRG;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
10:41 EDTMYLHigh option volume stocks
Subscribe for More Information
December 17, 2014
10:36 EDTATHNOptions with decreasing implied volatility
Subscribe for More Information
December 16, 2014
10:34 EDTATHNOptions with decreasing implied volatility
Options with decreasing implied volatility: TLM LE CIEN LULU RH ATHN PAY
09:52 EDTMYLFDA ruling on generic Celebrex reversed by appeals court
Subscribe for More Information
December 15, 2014
11:32 EDTATHNathenahealth removed from short-term buy list at Deutsche Bank
10:23 EDTATHNOptions with decreasing implied volatility
Options with decreasing implied volatility: LE CIEN LULU PETM RH ATHN ADBE
December 12, 2014
11:01 EDTATHNOptions with decreasing implied volatility
Subscribe for More Information
December 11, 2014
16:30 EDTATHNOn The Fly: Closing Wrap
Subscribe for More Information
08:41 EDTATHNathenahealth price target lowered to $110 from $120 at FBR Capital
Subscribe for More Information
07:32 EDTMYLMylan launches generic version of Hikma Maple's Robaxin injection
Subscribe for More Information
07:06 EDTMYLMylan launches generic version of Orapred ODT
Mylan announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. Mylan received final approval from the FDA for its Abbreviated New Drug Application for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions. Prednisolone Sodium Phosphate Orally Disintegrating Tablets had U.S. sales of approximately $19.9M for the 12 months ending September 30.
December 10, 2014
16:09 EDTATHNathenahealth says will invest in FY15 to support 30% booking growth goal
athenahealth said that in FY15, the company plans to continue to scale its operations and improve Non-GAAP Adjusted Gross Margin; plans to continue to invest in sales and marketing to support its bookings growth goal of 30%; plans to increase investment in research and development to support building its continuum of care services; and plans to scale general and administrative expenses overall, while strategically investing in select areas.
16:07 EDTATHNathenahealth sees FY15 adjusted EPS $1.20-$1.30, consensus $1.25
Subscribe for More Information
16:05 EDTATHNathenahealth backs FY14 EPS close to high end of 98c-$1.10, consensus $1.10
Subscribe for More Information
11:10 EDTATHNathenahealth added to the short-term buy list at Deutsche Bank
07:38 EDTMYLMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
December 8, 2014
11:30 EDTMYLLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
11:13 EDTATHNathenahealth volatility elevated into investor meeting
Subscribe for More Information
10:08 EDTATHNathenahealth to host investor meeting
Investor meeting to be held in Watertown, MA on December 11 at 8:30 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use